These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 30953449)

  • 1. Retention in care and virological failure among adult HIV+ patients on second-line ART in Rwanda: a national representative study.
    Nsanzimana S; Semakula M; Ndahindwa V; Remera E; Sebuhoro D; Uwizihiwe JP; Ford N; Tanner M; Kanters S; Mills EJ; Bucher HC
    BMC Infect Dis; 2019 Apr; 19(1):312. PubMed ID: 30953449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cross-sectional study to evaluate second line virological failure and elevated bilirubin as a surrogate for adherence to atazanavir/ritonavir in two urban HIV clinics in Lilongwe, Malawi.
    Ongubo DM; Lim R; Tweya H; Stanley CC; Tembo P; Broadhurst R; Gugsa S; Ngongondo M; Speight C; Heller T; Phiri S; Hosseinipour MC
    BMC Infect Dis; 2017 Jul; 17(1):461. PubMed ID: 28673254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug resistance mutations after the first 12 months on antiretroviral therapy and determinants of virological failure in Rwanda.
    Ndahimana Jd; Riedel DJ; Mwumvaneza M; Sebuhoro D; Uwimbabazi JC; Kubwimana M; Mugabo J; Mulindabigwi A; Kirk C; Kanters S; Forrest JI; Jagodzinski LL; Peel SA; Ribakare M; Redfield RR; Nsanzimana S
    Trop Med Int Health; 2016 Jul; 21(7):928-35. PubMed ID: 27125473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV viral suppression in TREAT Asia HIV Observational Database enrolled adults on antiretroviral therapy at the Social Health Clinic, the National Center for HIV/AIDS, Dermatology & STDs, Phnom Penh, Cambodia.
    Boettiger DC; Khol V; Durier N; Law M; Sun LP
    Antivir Ther; 2016; 21(8):725-730. PubMed ID: 27124891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in Johannesburg, South Africa.
    Fox MP; Berhanu R; Steegen K; Firnhaber C; Ive P; Spencer D; Mashamaite S; Sheik S; Jonker I; Howell P; Long L; Evans D
    Trop Med Int Health; 2016 Sep; 21(9):1131-7. PubMed ID: 27383454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viral load detection and management on first line ART in rural Rwanda.
    Ndagijimana Ntwali JD; Decroo T; Ribakare M; Kiromera A; Mugwaneza P; Nsanzimana S; Lynen L
    BMC Infect Dis; 2019 Jan; 19(1):8. PubMed ID: 30606128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. When patients fail UNAIDS' last 90 - the "failure cascade" beyond 90-90-90 in rural Lesotho, Southern Africa: a
    Labhardt ND; Ringera I; Lejone TI; Cheleboi M; Wagner S; Muhairwe J; Klimkait T
    J Int AIDS Soc; 2017 Jul; 20(1):21803. PubMed ID: 28777506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
    Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M;
    Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profile of HIV-infected patients receiving second-line antiretroviral therapy in a resource-limited setting in Nigeria.
    Onyedum CC; Iroezindu MO; Chukwuka CJ; Anyaene CE; Obi FI; Young EE
    Trans R Soc Trop Med Hyg; 2013 Oct; 107(10):608-14. PubMed ID: 23959002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retention and viral suppression in a cohort of HIV patients on antiretroviral therapy in Zambia: Regionally representative estimates using a multistage-sampling-based approach.
    Sikazwe I; Eshun-Wilson I; Sikombe K; Czaicki N; Somwe P; Mody A; Simbeza S; Glidden DV; Chizema E; Mulenga LB; Padian N; Duncombe CJ; Bolton-Moore C; Beres LK; Holmes CB; Geng E
    PLoS Med; 2019 May; 16(5):e1002811. PubMed ID: 31150380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retention in care among HIV-positive patients initiating second-line antiretroviral therapy: a retrospective study from an Ethiopian public hospital clinic.
    Wilhelmson S; Reepalu A; Balcha TT; Jarso G; Björkman P
    Glob Health Action; 2016; 9():29943. PubMed ID: 26765104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained virological response on second-line antiretroviral therapy following virological failure in HIV-infected patients in rural South Africa.
    Schoffelen AF; Wensing AM; Tempelman HA; Geelen SP; Hoepelman AI; Barth RE
    PLoS One; 2013; 8(3):e58526. PubMed ID: 23505529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
    Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
    PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low primary and secondary HIV drug-resistance after 12 months of antiretroviral therapy in human immune-deficiency virus type 1 (HIV-1)-infected individuals from Kigali, Rwanda.
    Rusine J; Asiimwe-Kateera B; van de Wijgert J; Boer KR; Mukantwali E; Karita E; Gasengayire A; Jurriaans S; de Jong M; Ondoa P
    PLoS One; 2013; 8(8):e64345. PubMed ID: 23950859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virological outcomes of antiretroviral therapy in Zomba central prison, Malawi; a cross-sectional study.
    Mpawa H; Kwekwesa A; Amberbir A; Garone D; Divala OH; Kawalazira G; van Schoor V; Ndindi H; van Oosterhout JJ
    J Int AIDS Soc; 2017 Aug; 20(1):21623. PubMed ID: 28782332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV care continuum in Rwanda: a cross-sectional analysis of the national programme.
    Nsanzimana S; Kanters S; Remera E; Forrest JI; Binagwaho A; Condo J; Mills EJ
    Lancet HIV; 2015 May; 2(5):e208-15. PubMed ID: 26423003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Descriptive analysis of World Health Organization-recommended second-line antiretroviral treatment: A retrospective cohort data analysis.
    Gumede SB; Fischer A; Venter WDF; Lalla-Edward ST
    S Afr Med J; 2019 Nov; 109(12):919-926. PubMed ID: 31865953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Third-Line Antiretroviral Therapy Program in the South African Public Sector: Cohort Description and Virological Outcomes.
    Moorhouse M; Maartens G; Venter WDF; Moosa MY; Steegen K; Jamaloodien K; Fox MP; Conradie F
    J Acquir Immune Defic Syndr; 2019 Jan; 80(1):73-78. PubMed ID: 30334876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Excellent clinical outcomes and high retention in care among adults in a community-based HIV treatment program in rural Rwanda.
    Rich ML; Miller AC; Niyigena P; Franke MF; Niyonzima JB; Socci A; Drobac PC; Hakizamungu M; Mayfield A; Ruhayisha R; Epino H; Stulac S; Cancedda C; Karamaga A; Niyonzima S; Yarbrough C; Fleming J; Amoroso C; Mukherjee J; Murray M; Farmer P; Binagwaho A
    J Acquir Immune Defic Syndr; 2012 Mar; 59(3):e35-42. PubMed ID: 22156912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.